There are 2137 resources available
350TiP - A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)
Presenter: Nicholas Turner
Session: E-Poster Display
Resources:
Abstract
351TiP - SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
Presenter: Mafalda Oliveira
Session: E-Poster Display
Resources:
Abstract
352TiP - EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract
353TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract
354TiP - Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
Presenter: Federico Rojo Todo
Session: E-Poster Display
Resources:
Abstract
356TiP - A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
Presenter: Hope Rugo
Session: E-Poster Display
Resources:
Abstract
355TiP - Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)
Presenter: Nicholas Turner
Session: E-Poster Display
Resources:
Abstract
357TiP - SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Presenter: Javier Cortés
Session: E-Poster Display
Resources:
Abstract
358TiP - Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
Presenter: Aditya Bardia
Session: E-Poster Display
Resources:
Abstract
359TiP - International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
Presenter: Peter Kaufman
Session: E-Poster Display
Resources:
Abstract